JP2015521466A5 - - Google Patents

Download PDF

Info

Publication number
JP2015521466A5
JP2015521466A5 JP2015516728A JP2015516728A JP2015521466A5 JP 2015521466 A5 JP2015521466 A5 JP 2015521466A5 JP 2015516728 A JP2015516728 A JP 2015516728A JP 2015516728 A JP2015516728 A JP 2015516728A JP 2015521466 A5 JP2015521466 A5 JP 2015521466A5
Authority
JP
Japan
Prior art keywords
antibody
seq
region
fragment
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015516728A
Other languages
English (en)
Japanese (ja)
Other versions
JP6433889B2 (ja
JP2015521466A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2013/054810 external-priority patent/WO2013186719A1/en
Publication of JP2015521466A publication Critical patent/JP2015521466A/ja
Publication of JP2015521466A5 publication Critical patent/JP2015521466A5/ja
Application granted granted Critical
Publication of JP6433889B2 publication Critical patent/JP6433889B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015516728A 2012-06-15 2013-06-12 Gdf−8に対する改善された拮抗抗体およびその使用 Expired - Fee Related JP6433889B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261660232P 2012-06-15 2012-06-15
US61/660,232 2012-06-15
PCT/IB2013/054810 WO2013186719A1 (en) 2012-06-15 2013-06-12 Improved antagonist antibodies against gdf-8 and uses therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018209932A Division JP2019059738A (ja) 2012-06-15 2018-11-07 Gdf−8に対する改善された拮抗抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2015521466A JP2015521466A (ja) 2015-07-30
JP2015521466A5 true JP2015521466A5 (https=) 2016-07-28
JP6433889B2 JP6433889B2 (ja) 2018-12-05

Family

ID=48914383

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015516728A Expired - Fee Related JP6433889B2 (ja) 2012-06-15 2013-06-12 Gdf−8に対する改善された拮抗抗体およびその使用
JP2018209932A Pending JP2019059738A (ja) 2012-06-15 2018-11-07 Gdf−8に対する改善された拮抗抗体およびその使用
JP2020124373A Withdrawn JP2021001170A (ja) 2012-06-15 2020-07-21 Gdf−8に対する改善された拮抗抗体およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018209932A Pending JP2019059738A (ja) 2012-06-15 2018-11-07 Gdf−8に対する改善された拮抗抗体およびその使用
JP2020124373A Withdrawn JP2021001170A (ja) 2012-06-15 2020-07-21 Gdf−8に対する改善された拮抗抗体およびその使用

Country Status (20)

Country Link
US (4) US8992913B2 (https=)
EP (1) EP2861617A1 (https=)
JP (3) JP6433889B2 (https=)
KR (1) KR101704893B1 (https=)
CN (1) CN104487453B (https=)
AR (1) AR093217A1 (https=)
AU (1) AU2013276131B2 (https=)
CA (1) CA2876397C (https=)
CO (1) CO7151524A2 (https=)
IL (1) IL236289A0 (https=)
MX (1) MX364738B (https=)
MY (1) MY177331A (https=)
NZ (1) NZ702269A (https=)
PE (1) PE20150223A1 (https=)
PH (1) PH12014502698B1 (https=)
RU (1) RU2630634C2 (https=)
SA (1) SA113340642B1 (https=)
SG (1) SG11201408042YA (https=)
TW (1) TWI495643B (https=)
WO (1) WO2013186719A1 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
TWI812066B (zh) 2010-11-30 2023-08-11 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
AU2012339722B2 (en) 2011-11-14 2017-09-14 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A
EP2861617A1 (en) * 2012-06-15 2015-04-22 Pfizer Inc. Improved antagonist antibodies against gdf-8 and uses therefor
EP3597747B1 (en) 2012-08-24 2023-03-15 Chugai Seiyaku Kabushiki Kaisha Mouse fcgammarii-specific fc antibody
TW202237660A (zh) 2012-08-24 2022-10-01 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
TWI633117B (zh) 2012-09-13 2018-08-21 必治妥美雅史谷比公司 結合至肌肉生長抑制素(myostatin)以纖維連接蛋白爲主之支架結構域蛋白質
EA201590719A1 (ru) 2013-01-25 2015-12-30 Шир Хьюман Дженетик Терапис, Инк. Фоллистатин в лечении мышечной дистрофии дюшенна
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
HRP20251426T1 (hr) 2013-05-06 2026-01-02 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素a之抗體及其用途
US9994641B2 (en) * 2013-12-25 2018-06-12 Jcr Pharmaceuticals Co., Ltd. Anti-human transferrin receptor antibody that passes through blood-brain barrier
HK1243940A1 (zh) 2014-11-06 2018-07-27 Scholar Rock, Inc. 抗原肌肉生长抑制素/潜在肌肉生长抑制素的抗体及其用途
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
CN104829728B (zh) * 2015-01-21 2019-03-12 武汉友芝友生物制药有限公司 一种双特异性抗体her2xcd3的构建及应用
CN114773470A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用
EA201792184A1 (ru) 2015-04-01 2018-04-30 Анаптисбайо, Инк. Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3)
WO2016168613A1 (en) * 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
LT3350220T (lt) 2015-09-15 2021-09-27 Scholar Rock, Inc. Anti pro/latentinio miostatino antikūnai ir jų panaudojimas
TWI605057B (zh) 2015-12-18 2017-11-11 中外製藥股份有限公司 抗肌抑素抗體、含變異fc區之多肽及使用方法
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
CN109069638B (zh) 2016-03-24 2022-03-29 璟尚生物制药公司 用于癌症治疗的三特异性抑制剂
AU2017283546C1 (en) 2016-06-13 2020-11-19 Scholar Rock, Inc. Use of myostatin inhibitors and combination therapies
KR102306744B1 (ko) 2016-06-17 2021-09-28 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체 및 사용 방법
CA2971303C (en) 2016-06-21 2026-03-03 Bamboo Therapeutics, Inc. Optimized mini-dystrophin genes and expression cassettes and their use
TWI693940B (zh) 2016-08-05 2020-05-21 日商中外製藥股份有限公司 Il-8相關疾病之治療用或預防用組成物
SG11201903867YA (en) 2016-11-01 2019-05-30 Anaptysbio Inc Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
CN109071656B (zh) 2017-01-05 2021-05-18 璟尚生物制药公司 检查点调节物拮抗剂
ES2944357T3 (es) 2017-01-06 2023-06-20 Scholar Rock Inc Tratamiento de enfermedades metabólicas inhibiendo la activación de miostatina
MX2019008208A (es) 2017-01-09 2019-12-11 Tesaro Inc Métodos para tratar el cáncer con anticuerpos anti-tim-3.
WO2018156711A1 (en) * 2017-02-22 2018-08-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Il13ra2-binding chimeric antigen receptors
CN111787981B (zh) 2018-03-01 2025-12-30 瑞泽恩制药公司 增加肌肉量和减少脂肪量的方法
CN113101364B (zh) 2018-05-29 2023-12-01 康诺亚生物医药科技(成都)有限公司 一种自免疫抑制剂的开发和应用
CN112739717B (zh) 2018-06-29 2025-02-11 璟尚生物制药公司 三特异性拮抗剂
EP3990030A1 (en) 2019-06-27 2022-05-04 Pfizer Inc. Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
US10851157B2 (en) 2019-07-01 2020-12-01 Gensun Biopharma, Inc. Antagonists targeting the TGF-β pathway
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
EP4232071A4 (en) * 2020-10-23 2024-08-28 Asher Biotherapeutics, Inc. FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION
WO2022106976A1 (en) 2020-11-18 2022-05-27 Pfizer Inc. Stable pharmaceutical formulations of soluble fgfr3 decoys
AU2022275666A1 (en) 2021-05-19 2023-12-07 Asher Biotherapeutics, Inc. Il-21 polypeptides and targeted constructs
MX2023014840A (es) 2021-06-23 2024-02-12 Scholar Rock Inc Un inhibidor de la vía de la miostatina en combinación con un activador de la vía de la glp-1 para su uso en el tratamiento de trastornos metabólicos.
US20250257131A1 (en) * 2022-04-08 2025-08-14 The Wistar Institute Of Anatomy And Biology Bispecific T Cell Engagers Targeting Tumor Antigens
CN120187750A (zh) * 2022-09-21 2025-06-20 瑞泽恩制药公司 治疗肥胖、糖尿病和肝功能障碍的方法
IL321628A (en) 2022-12-22 2025-08-01 Scholar Rock Inc Selective and potent inhibitory antibodies for myostatin activation

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
WO1990013327A1 (en) 1989-04-28 1990-11-15 Riker Laboratories, Inc. Dry powder inhalation device
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE69424687T2 (de) 1993-03-09 2000-09-07 Genzyme Corp., Cambridge Verfahren zur isolierung von proteinen aus milch
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US6673534B1 (en) 1995-10-26 2004-01-06 The Johns Hopkins University School Of Medicine Methods for detection of mutations in myostatin variants
DK0690873T3 (da) 1993-03-19 2003-09-29 Univ Johns Hopkins Med Vækstdifferentieringsfaktor-8
US20030074680A1 (en) 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US6465239B1 (en) 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US7332575B2 (en) 1994-03-18 2008-02-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
US6046037A (en) 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5695760A (en) 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
SE9502800D0 (sv) 1995-08-10 1995-08-10 Astra Ab Disposable inhaler
EP0869815A1 (en) 1995-09-21 1998-10-14 University Of Utah Research Foundation Targeting of conjugates of poly(ethylene glycol) and antibodies against glutamic acid decarboxylase to islet cells
WO1998033887A1 (en) 1997-02-05 1998-08-06 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
DE69841139D1 (de) 1997-07-14 2009-10-22 Univ Liege Mutationen im myostatingen steigern muskelmasse in säugetieren
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
AU8666398A (en) 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
US6372454B2 (en) 1997-08-29 2002-04-16 Human Genome Sciences, Inc. Nucleic acid molecules encoding Follistatin-3
WO1999024618A1 (en) 1997-11-10 1999-05-20 The Johns Hopkins University School Of Medicine Methods for detection of mutations in myostatin variants
WO1999040181A1 (en) 1998-02-05 1999-08-12 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
ES2330062T3 (es) * 1998-05-06 2009-12-03 Metamorphix, Inc. Procedimientos para tratar la diabetes por inhibicion de gdf-8.
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
AU772694B2 (en) 1999-01-21 2004-05-06 Metamorphix International, Inc. Growth differentiation factor inhibitors and uses therefor
US7056512B1 (en) 1999-07-20 2006-06-06 Pharmexa A/S Method for down-regulating GDF-8 activity
AU1097301A (en) * 1999-10-22 2001-05-08 Scripps Research Institute, The Humanization of non-human, mammalian antibodies
US7037501B2 (en) 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
CU23007A1 (es) 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
US20040058445A1 (en) 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
CA2476887A1 (en) 2002-02-21 2003-09-04 Wyeth Gasp1:a follistatin domain containing protein
BR0307871A (pt) 2002-02-21 2005-04-12 Wyeth Corp Proteìnas contendo domìnio de folistatina
US20040110933A1 (en) * 2002-09-13 2004-06-10 Dyax Corporation CD44-binding ligands
AR047392A1 (es) * 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
BRPI0410927A (pt) * 2003-06-02 2006-06-27 Wyeth Corp métodos terapêuticos e profiláticos para distúrbios neuromusculares
ATE557042T1 (de) * 2004-03-23 2012-05-15 Lilly Co Eli Anti-myostatin-antikörper
PE20100251A1 (es) * 2004-09-10 2010-04-10 Wyeth Corp Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
AU2006232914A1 (en) 2005-03-23 2006-10-12 Wyeth Detection of an immune response to GDF-8 modulating agents
CA2601667A1 (en) 2005-03-23 2006-09-28 Wyeth Detection of gdf-8 modulating agents
NL1031674C2 (nl) * 2005-04-25 2007-04-26 Pfizer Antilichamen tegen myostatine.
ES2534760T3 (es) * 2005-08-19 2015-04-28 Wyeth Llc Anticuerpos antagonistas contra GDF-8 y sus usos en el tratamiento de ELA y otros trastornos asociados con GDF-8
WO2008073598A2 (en) * 2006-10-31 2008-06-19 Immunogen, Inc. Methods for improving antibody production
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
EP2861617A1 (en) * 2012-06-15 2015-04-22 Pfizer Inc. Improved antagonist antibodies against gdf-8 and uses therefor

Similar Documents

Publication Publication Date Title
JP2015521466A5 (https=)
RU2014150433A (ru) Улучшенные антитела антагонисты против gdf-8 и их применения
JP2019201643A5 (https=)
JP2017052784A5 (https=)
RU2015136078A (ru) Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний
FI3322727T3 (fi) Humanisoituja tai kimeerisiä CD3-vasta-aineita
JP2018183173A5 (https=)
JP2014511179A5 (https=)
HRP20220405T1 (hr) Protutijela protiv ngf i njihova upotreba
IL261666B1 (en) Binding proteins and methods of use thereof
JP2018512138A5 (https=)
HRP20170568T1 (hr) Protutijela anti-ox40 i postupci za njihovu uporabu
JP2019530427A5 (https=)
NZ597996A (en) Antibodies against human respiratory syncytial virus (rsv) and methods of use
HRP20220787T1 (hr) Protutijela protiv garp-tgf-beta
HRP20210892T1 (hr) Terapijska uporaba specifičnog liganda u bolestima povezanim s msrv
PE20120835A1 (es) Anticuerpos anti-tnf-alfa y sus usos
JP2017535257A5 (https=)
RU2017126476A (ru) Новые модуляторы и способы их применения
JP2016529882A5 (https=)
RU2016100892A (ru) Антитела против tweakr и их применение
JP2015525795A5 (https=)
RU2017134495A (ru) Антитела к альфа-рецептору собачьего интерлейкина-4
EP2377555A3 (en) Antibodies against vascular endothelial growth factor receptor-1
JP2014519334A5 (https=)